(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...
Stats | |
---|---|
Dagens volum | 4.69M |
Gjennomsnittsvolum | 4.77M |
Markedsverdi | 26.92B |
EPS | €0 ( 2024-03-04 ) |
Neste inntjeningsdato | ( €2.32 ) 2024-05-14 |
Last Dividend | €2.40 ( 2023-05-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | -9.16 |
ATR14 | €0.0150 (0.05%) |
Volum Korrelasjon
Bayer AG Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Bayer AG Korrelasjon - Valuta/Råvare
Bayer AG Økonomi
Annual | 2023 |
Omsetning: | €47.64B |
Bruttogevinst: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2023 |
Omsetning: | €47.64B |
Bruttogevinst: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2022 |
Omsetning: | €50.74B |
Bruttogevinst: | €30.87B (60.84 %) |
EPS: | €4.22 |
FY | 2021 |
Omsetning: | €44.08B |
Bruttogevinst: | €27.27B (61.85 %) |
EPS: | €1.018 |
Financial Reports:
No articles found.
Bayer AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€2.40 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €1.279 | 2000-05-02 |
Last Dividend | €2.40 | 2023-05-02 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €43.29 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.56 | -- |
Div. Sustainability Score | 3.23 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 2.71 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
INS.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
SY1.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
DAM.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% | |
LXS.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
2X0.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
VH2.F | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
EOAN.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
NWT.DE | Ex Dividend Knight | 2023-08-03 | Quarterly | 0 | 0.00% | |
AISF.F | Ex Dividend Knight | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
GUI.DE | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0617 | 1.500 | -1.235 | -1.852 | [0 - 0.5] |
returnOnAssetsTTM | -0.0238 | 1.200 | -0.795 | -0.954 | [0 - 0.3] |
returnOnEquityTTM | -0.0816 | 1.500 | -2.02 | -3.03 | [0.1 - 1] |
payoutRatioTTM | -0.809 | -1.000 | -8.09 | 8.09 | [0 - 1] |
currentRatioTTM | 1.259 | 0.800 | 8.70 | 6.96 | [1 - 3] |
quickRatioTTM | 0.784 | 0.800 | -0.0946 | -0.0757 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.355 | -1.500 | 4.08 | -6.11 | [0 - 0.6] |
interestCoverageTTM | 0.595 | 1.000 | -0.891 | -0.891 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 8.97 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.332 | -1.500 | 4.67 | -7.01 | [0 - 2.5] |
grossProfitMarginTTM | 0.585 | 1.000 | 3.58 | 3.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0333 | 1.000 | -1.333 | -1.333 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.109 | 1.000 | -0.507 | -0.507 | [0.2 - 2] |
assetTurnoverTTM | 0.386 | 0.800 | -0.759 | -0.607 | [0.5 - 2] |
Total Score | 3.23 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.15 | 1.000 | -1.026 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0816 | 2.50 | -1.297 | -3.03 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 9.32 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.76 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.809 | 1.500 | -8.09 | 8.09 | [0 - 1] |
pegRatioTTM | 0.117 | 1.500 | -2.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.100 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.